Mebutan Dispers (Nabumetone)

Nabumetone is a pro‑drug that is rapidly converted to its active metabolite, which reversibly inhibits cyclooxygenase‑1 and cyclooxygenase‑2 enzymes. This inhibition decreases prostaglandin synthesis, leading to reduced inflammation, pain and fever.

The prescribed dose of nabumetone is determined by the treating physician based on the individual’s condition, severity, renal and hepatic function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety of nabumetone in pregnancy and lactation has not been established. It is generally advised to avoid use during pregnancy, especially in the third trimester, and to discontinue breastfeeding while taking the medication unless the benefits outweigh potential risks as assessed by a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Mebutan Dispers. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nabumetone is a non‑selective COX inhibitor like ibuprofen or naproxen, but it is a pro‑drug that may have a lower incidence of gastrointestinal irritation in some patients. Its analgesic potency is comparable, and safety considerations such as renal and cardiovascular risk remain similar across the NSAID class.

Store at room temperature, preferably below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged or the tablets appear discolored.

Mebutan Dispers is taken orally, usually with food or a full glass of water to reduce gastrointestinal discomfort. The tablet should be swallowed whole and not crushed, chewed, or split unless specifically instructed by a healthcare professional.

Serious adverse events, although uncommon, include peptic ulcer disease, gastrointestinal bleeding, severe skin reactions such as Stevens‑Johnson syndrome, hepatic injury, renal impairment and cardiovascular events like myocardial infarction. Patients should seek immediate medical attention if they experience symptoms such as black stools, severe abdominal pain, rash or swelling.

Individuals with a known hypersensitivity to nabumetone or other NSAIDs, active peptic ulcer disease, severe heart failure, uncontrolled hypertension, significant renal or hepatic impairment, and those who have experienced serious cardiovascular events should avoid using Mebutan Dispers unless a physician determines that the benefits outweigh the risks.